Hey, everyone. Thank you for joining us today for the NewMed Energy Financial Results of 2024 webinar. All participants are in listen mode only. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I'm pleased to introduce Yossi Abu, CEO of NewMed Energy. Yossi, you may begin. Thank you very much, everybody, for joining us this afternoon, basically to cover our financial reports for 2024 and Q4 2024. With your permission, we'll start with the key highlights. I think that we basically meet our target for 2024 when we met production of a little bit short of 1.1 BCF a day earlier this year. In the fourth quarter, we arrived to 1.06 BCF a day. Our target for 2025 is reaching a bit higher than 1.1 BCF, getting to 11.6 BCM target to our guidance for 2025. We will cover today as well our brown field expansion. We'll deal with the third gathering line that we are due to finish by the end of the year, early next year, taking us from the 1.2 BCF a day capacity currently that we have to the 1.4 BCF a day early next year. We are as well progressing with the phase 1B of Leviathan. We submitted the full updated development plan to our oil commissioner for approval. We are continuing with the FEED process to be able to take investment decisions by mid this year. On top of that, on Aphrodite field, we already agreed with the development plan with the Cyprus government. They approved our submitted development plan. We signed recently an MoU between Cyprus, Egypt, and Aphrodite partners in order to develop the field and supply the gas to the Egyptian market. We will cover that as well. We announced this morning another $60 million dividend, a total of $250 million dividend for 2024, around 6% dividend yield for NewMed Energy. Our target is basically to continue with this dividend policy in parallel to the investment in developing Leviathan second phase and developing Aphrodite. The main reason is because we basically build Leviathan in a modular way. We will have an increase in sales this year and next year and the following year. Together with another debt, we'll be able to continue and maintain investment, a reasonable debt position, and dividend stream. The production summary, if I'm taking the head of the year, as I mentioned, we arrived to 11.2 BCM, around 1.1 BCM this year, around 1.1 BCM a day sales. From pricing perspective, the average price of this year is very similar to the average price of last year, mainly because of our positioning vis-à-vis Brent in our agreement. I will touch that. As you can see, in all our agreements, we built a floor price that will protect us from the downside of the Brent. We can enjoy as well some of the upside. You can see month by month since we started production in Leviathan, where we are achieving the average price with respect to the Brent price. That gives us a long-term stability. We understand exactly what's going to be our income many years to come. We can continue to invest and sustain dividends. The fourth quarter, as you can see, we basically sell around 2.7 BCM in the fourth quarter. It was a little bit short of the last quarter. We arrived to $264 million sales. EBITDA, we reached $181 million, $10 million less than Q4 2023. Net profit of $120 million. When we are looking on the average yearly, we basically increased our sales at around $40 million. This is due mainly to the additional condensate sales that we have. We reached EBITDA of $785 million. In net profit, we increased our net profit then in more than 20% from $434 million- $525 million in 2024. Meaningful increase in the net profit for NewMed Energy. When we look on the expansion of second phase of Leviathan, we are definitely running with our timetable and continue with the expansion. We received from the oil commissioner a green light on the boundaries for the new gas agreement for second phase. We received approval to export between 118 BCM and 145 BCM on top of all the agreements to export that we already have. In order to basically the first agreement to Egypt was 64 BCM total security in the agreement. As we announced this morning, we are targeting for a new agreement with Egypt with addition more than 100 BCM in addition to the 64. This is under negotiation. We are going as well to sign more agreement in the local market to cover second phase of Leviathan. As I mentioned, we submitted to the Israeli oil commissioner to his approval the updated development plan for Leviathan, including the second phase. That includes three additional producing wells, including subsea system, and as well the expansion of the platform. We are going to expand the platform and to add two additional treatment trains to the three that already exist. That will bring us to a capacity of 2.1 BCF a day, 21 BCM a year. If we will add the fourth gathering line, we will reach even 2.3 BCF a day for the facility. The CapEx that we currently have for second phase is $2.4 billion. This is on top of the $500 million that we are already investing in FEED. We are targeting to take investment decisions mid this year. In parallel to the upstream activity and increasing the upstream capability, we are working as well to increase the midstream capability in order to have more routes and more capacity to the Egyptian market. EMG, we are due to finish the looping of Ashdod- Ashkelon that will allow us to bring more gas to the EMG pipeline. Currently, EMG is working in 600 million SCF a day. We are estimating that post the looping of Ashdod-Ashkelon, we will be in 850. Out of it, 650 belong to Leviathan. It is a Leviathan capacity. That will be by Q1 2026. On top of that, we are increasing the capacity in the Fajr pipeline, adding compression system in Jordan. That compression system that due to come by in the first half of 2026 will bring us to 700-750 MMCF a day to Leviathan capacity. Basically, together with Nitzana, which we are estimating 600 million SCF a day total capacity, which Leviathan capacity is 300, Leviathan will have 1.6 BCF a day to the Egyptian market. This is more than enough to cover all our activity, including phase two. On the Aphrodite field, we approved the development plan that we submitted to the Cyprus government. The Cyprus government is aligned with that, including milestone to the activity. We are very keen to develop this project. We submitted the development plan that basically will have a floater that will create around 800 million SCF a day, 8 BCM a year. The target is to sell it to the Egyptian market. We signed MoU with the Egyptian government, in order to establish the framework and the umbrella for the development of Aphrodite. We are entering into a negotiation with respect to a new GSPA to cover that capacity to the Egyptian market. On top of that activity, we are also preparing our new discoveries for future development. We have three main activities. One is Block I in offshore Israel, triangle of Israel, Cyprus, and Lebanon in the north. This is a partnership between SOCAR, BP, and NewMed, one third, one third, one third. We are basically due to receive the block and to sign the license during this month. In this license, SOCAR is the operator. This is an area that is yet to be explored in the Israeli offshore. That is an area which is sitting very close to Tamar, Leviathan, Karish, Tanin, so in the heart of the activity. We are really keen to start a 3D campaign there to understand whether we have leads and prospects to lead to drill zones. In Morocco, we received a very large license. That license inside is equivalent to all the offshore Israel. What we are doing right now, we are in the middle of a 3D reprocessing campaign in order to analyze all the data that has been there for the last year. Basically trying to, again, identify the leads and the prospects. Based on the reprocessing, we decide whether we are going to drill or we need more 3D work on the area. This is where we are in the middle of the campaign. In Bulgaria, we just signed agreement to farm into Han Asparuh. It's an offshore license owned by OMV. OMV Petrom is the operator. Our first prospect to be drilled and there's potentially more prospects there is a 2 TCF prospect with high chance of geological success. We're talking about 43%. Very promising from our side. This license is really sitting in the triangle of Romania, Bulgaria, and Turkey in between the discoveries in the Turkish EEZ and the Romanian EEZ. Same geological concept. We hope and really hope to see the same results, meaning commercial discovery. Our target is to start the well, to start and drill the well during Q4 this year. Now I'll move to Tzachi Habusha, our CFO, to cover the P&L and the financial report. We'll come back to me for final words and questions. Thank you, Yossi. Thank you all for joining us today. I would like to share a few points regarding the financial, the annual financial statement. Let's go to the bottom line, as was mentioned. We are summarizing 2024 with revenues of approximately $1.14 billion and about 11.2 BCM, which were produced from Leviathan reservoir. These are higher figures compared to 2023, which ended with revenues of $1.1 billion and 11 BCM. NewMed net income for 2024 stands at approximately $525 million, about 21% higher than last year's profit of $433 million. The growth in NewMed net income is mainly due to an increase in natural gas and condensate sales and the reduction in net financial expenses, as I will expose later. The net profit in Q4 is approximately $120 million compared to $102 million in the same period last year, about 18% higher. Here's a very good slide that we can see the main changes in the net profit compared to the same period last year. The net revenues for 2024 increased by $39 million. This includes a $1.1 million increase due to a better average gas price per MMBtu and a $20.6 million increase due to a higher natural gas sale. In addition, we received in 2024, as Yossi mentioned, about $17 million from the sale of condensate, which started in March 2024. We also present a decrease, a material decrease in net financial expenses of $82 million. This is mainly due to the reevaluation of Karish and Tanin royalties, the full repayment of Leviathan bond series June 2023, and the implementation of the buyback program. Other factors, as you can see, affecting our net income include a $14 million decrease in operating expenses and about $14 million decrease in tax expenses. Two points regarding the balance sheet report. First, our financial assets related to Karish and Tanin royalties. That asset was recognized following the sale of NewMed interest in Karish and Tanin Ltd. in 2016. As of the date of this financial statement, the fair value of these assets is approximately $278 million, which presented in long-term assets and short-term receivables. Second, the total debt is about $1.6 billion, consisting of Leviathan bonds with maturity dates in 2025, 2027, and 2030. The 2025 series is presented in short-term liabilities with the buyback deduction. These bonds with fixed interest rates left us in a strong financial position and positively impacted our financial costs. We have also significantly reduced our debt position. By the end of June 2023, we retained the Leviathan bond in the amount of $500 million. As of the reported full debt, we repurchased approximately $135 million from Leviathan bond series June 25, and we are fully prepared for the next repayment of series June 25. The reduction in 2021 is due to the repayment of Tamar bonds and series A bonds. The last slide is about the distribution. As Yossi mentioned, the partnership declared a $60 million profit distribution following a total distribution of $250 million during 2024, which has been paid. Yossi, that concludes the key points regarding the annual financial statement. Thank you all. Thank you. Thank you very much. Just to build on what you said, basically, as you can see by the DCF here, our net debt based on Leviathan will be around $1.1 billion. Net value and PV of Leviathan is higher than $5.5 billion based on our recent DCF, and this is without even the second phase. What we are targeting to do, and this is something that we'll evaluate, is to be in the market to raise additional debt in order to first give us what we need to invest in the second phase of Leviathan, to invest in Aphrodite, and in parallel, maintaining the dividend policy. We are considering basically a few alternatives. One is to come to the market with additional bullets on Leviathan bonds according to the current structure. Another one is opportunities that we have around the Israeli market to raise at the corporate level and as well some opportunities in, let's call it, in a private activity. This is something that we will see, and we are following to see what is the best approach for NewMed. Now we will move to Q&A. Please, if somebody has a question, you have a Q&A. Sure. Yeah. I believe that basically most of the questions I answered through the slides, but let's start with the exploration activity. Basically, when we are taking a license, we are trying to understand and to find out whether we can have kind of additional value to the license. Our expertise in geology is very clear in the region, and we try to find a geological area that has some similarity to our region. This is why we go to Morocco. This is why we go to the Black Sea. There's some similarity because it's all geology that's based on all the rivers' activity: the Nile in the East Med, the Danube in the Black Sea, and Boujdour in Morocco. What we are seeing in Bulgaria in the license in Han Asparuh is first a first prospect to be drilled. This is already approved. This is something that we are running called Vinekh. This is a 2 TCF potentially with a 43%. The interesting thing for us is vis-à-vis our activity when we basically have a regional market, the East Med by pipeline. In Bulgaria, we are entering directly through the European market. Bulgaria has connections to other countries. Potentially, even we can ride on TANAP owned by SOCAR to get into the Balkan and the Italian market and to enjoy the TTF board in terms of prices. That is kind of what we are seeing. This is not the only prospect there. We identify more prospects, the OMV, the operator leading the activity, and hopefully, we will come back to the market and say what we have more once we are ready. This is for the additional licenses that we have. On the capacity of the Leviathan, the second phase of Leviathan without the fourth gathering line brings us to a capacity of 2.1 BCM a day. Adding the fourth gathering line brings us to 2.3 BCM a day, around 23 BCM a year. This is basically the capacity of the second phase. I think that we covered the questions. Thank you very much for your participation. If you have any additional questions or inquiries, you can approach Gil Bashan, and hope to see you soon. Thank you very much. I'm looking forward to getting your follow-up in the coming days. Let's be in touch. Thank you. Thank you.